---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-26-000043"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2026-08-10T20:05:14+00:00"
generated_at: "2026-08-10T20:06:25.606812+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bionano Q2 2026 revenue up 21% to $8.2M; fully retires secured convertible debentures

## Summary
- Q2 revenue $8.2M, up 21% YoY from $6.7M; consumables revenue $4.3M, up 31%.
- Sold 9,219 flow cells (+27% YoY); gross margin 53% vs 52% in Q2 2025.
- Operating expenses $11.5M (+2%); adjusted operating expense $8.7M (-2%).
- Completed full retirement of all Senior Secured Convertible Debentures, releasing asset liens.
- Alex Hastie returned as Chief Scientific Officer; T-ALL study showed OGM detected abnormalities in 97.8% of cases vs 55% by karyotyping.

## SEC filing metadata
- accession: 0001411690-26-000043
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2026-08-10T20:05:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/0001411690-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/bngo-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-26-000043
- JSON: https://secwatch.observer/filing/0001411690-26-000043.json
- Plain text: https://secwatch.observer/filing/0001411690-26-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.